Home / Speakers / Dr. Kamla Al-Salmani

Dr. Kamla Al-Salmani

The Novel mechanical effect of frankincense analogise acetyl-11-keto-β-boswellic-acid (AKBA) in the Hallmarks of cancer cells

By Dr. Kamla AL-Salmani

Frankincense have been historically important in many of Asian countries medicine for the treatment of  diverse range of conditions, many of which, with modern understanding it start merging to cancer treatment. In this review we are trying to focus in the biological and mechanical effect of AKBA in the hallmarks of cancer cells.

AKBA which is makes around 3.7% of approximately of a 200 triterpenes in frankincense found scientifically to play a very important role in many diseases including of cancer treatments. Hence, this compound was investigated by numerous of researchers, both in vitro and in vivo. It was able to show a significant effect in most of the cancer hallmarks using many cancer types in vitro, in vivo and in clinical trials. Altogether these studies were able to prove that AKBA has a direct effect in inhibition of cancer cell proliferation by induction of key apoptotic mediators through mechanisms involving p53 pathway through the activation of caspas-3 and Caspase-8 and inhibition of WNT and NFϰB pathways. It inhibits angiogenesis through the inhibition of FGFβ and VEGF by inhibiting the downstream kinases of VEGF Receptor 2 such as Src family kinase, AKT, and Mammalian target of rapamycin (mTOR). It was able to shows cell cycle arrest in cancer cells at G1 phase and display increase apoptosis. AKBA may be able to inhibit the kinases of signalling pathways downstream of multiple cytokines and growth factors may be of great relevance in its use as a cancer therapeutic.

These studies has shown a direct effect of AKBA in the cancer cell mechanism and may boosting the immune system to target cancer cells; which altogether provided a promising data of this compound to be able to take it further in the clinical trials as a future Novel cancer treatment. 


Dr. Kamla AL-Salmani is an active researcher in cancer treatment. She started Genetic diagnosis in Oman and she has worked as a Senior Lab staff in-charge in the Cytogenetic Department at Central Public Health for 13 years and 6 years as a Head of Cytogenetic Laboratories at National Genetic Center, Royal Hospital, Ministry of Health, Oman.

Her major achievement is starting Heamato-ocolgy diagnosis at genetics lab in MOH, and now serving all the heamato-oncology cases which come from all the main hospitals in Muscat.